Results 111 to 120 of about 1,580 (184)

Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]

Eur Heart J Case Rep
Seghers HM, Ectors B, Alaerts M, Saenen J, Van Craenenbroeck EM.   +4 more
europepmc   +1 more source

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]

JACC Case Rep
Kitai T, Zhang J, Saku K.
europepmc   +1 more source

Obstructive Hypertrophic Cardiomyopathy With Degenerative Mitral Regurgitation: A New Treatment Strategy Using Mavacamten Combined With M-TEER. [PDF]

JACC Case Rep
Wang Y, Liu X, Ma L, Liu Y, Cao Y, An G, Liu F, Dong M.   +7 more
europepmc   +1 more source

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Ibrahim R, Wang W, Pham HN, Abdelnabi M, Lester SJ, Wilansky S, Schaff HV, Geske JB, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Mavacamten Reduces LVOT Obstruction Risk, Enabling Transseptal Mitral Valve-in-Valve for Degenerated Bioprosthesis. [PDF]

JACC Case Rep
Hoss A, Voß F, Polzin A.
europepmc   +1 more source

Left ventricular flow components and myocardial deformation following treatment for hypertrophic obstructive cardiomyopathy: a retrospective cardiac magnetic resonance-based cohort of mavacamten <i>vs.</i> septal myectomy. [PDF]

Cardiovasc Diagn Ther
Chen Y, Luo X, Yang Y, Ou J, Liu H.
europepmc   +1 more source

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]

Eur Heart J Suppl
Biagini E, Schiavo MA.
europepmc   +1 more source

Paradoxical Pulmonary Congestion After Mavacamten in Obstructive HCM: A Case Illustrating Hemodynamic Transition. [PDF]

JACC Case Rep
Tabata N, Izumiya Y, Nomura N, Kuyama N, Yamamoto E, Tsujita K.   +5 more
europepmc   +1 more source

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]

JACC Case Rep
Polizzi R, Canciello G, Ordine L, Lombardi R, Esposito G, Losi MA.   +5 more
europepmc   +1 more source

Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. [PDF]

ESC Heart Fail
Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W, Martens P.   +6 more
europepmc   +1 more source